Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 151

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4A
Chunk 151
---
 or rigid selection criteria, but instead focused on a combination of the factors
and individual attributes of the Lead Projects themselves. See “ Item 3. Key Information - D. Risk Factors - Risks Related
to the Preclinical and Clinical Development of Our Drug Candidates - “ Preclinical development is a long, expensive and uncertain
process, and we may terminate one or more of our current preclinical development programs.” and “ Management has discretion
to terminate the development of any of our projects at any time.”

Our goal is to develop a broad
range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components
of our strategy for achieving this goal include: (for details of our strategy, See “ Item 4. Information on the Company - B.
Business Overview - Our Strategy”)

  Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas;  

  Selectively expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs;  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Collaborating with leading academic institutions and CROs;  

  Expanding our in-house pharmaceutical development center;  

  Leveraging our management’s expertise, experience, and commercial networks;  

  Obtaining and leveraging government grants to fund project development.  

We have devoted a substantial
portion of the proceeds from our offerings to our Lead Projects. Our Lead Projects are ALS-4, SACT-1 and PathsDxTest. In March
2023, we announced that we completed the Pre-IND discussions with the US FDA on ALS-4. With the positive feedback on the overall development
strategy from the US FDA, we are proceeding towards the IND submission of ALS-4. In March 2023, we also announced the completion of the
End of Phase 1 (EOP1) meeting of SACT-1 with the US FDA. The FDA generally agreed with the chemistry-manufacturing-control (CMC) strategy
and our proposed clinical development plan for SACT-1 Phase 1/2 trials. We commenced clinical validation of our molecular based PathsDxTest and will continue to undergo validations in parallel with its pre-commercialization process.

During the second quarter
of 2023, the Company made a decision to streamline its operations by terminating clinic services and suspending non-lead R& D projects